Overview Request Sample Pages Request Customization Download PDF
You are viewing: US Tissue Diagnostics Market analysis
Part of: Tissue Diagnostics Market (Global)

The US Tissue Diagnostics Market was valued at $1454.8 Million in 2025 and projected to reach to $2339.9 Million by 2030, representing a compound annual growth rate of 10.0%. The US tissue diagnostics market is positioned for sustained expansion through 2030, driven by rising cancer incidence rates, growing demand for precision medicine, and increasing healthcare expenditure.

US Tissue Diagnostics Market Trends and Insights

  • This expansion reflects the US healthcare system's increasing reliance on advanced diagnostic technologies for cancer detection, pathology analysis, and personalized medicine.
  • The US market benefits from strong healthcare infrastructure, high adoption rates of innovative diagnostic solutions, and substantial investment in research and development. Driving this growth, the US tissue diagnostics sector is supported by rising cancer incidence, growing demand for precision medicine, and regulatory support for advanced diagnostic platforms.
  • The US market's maturity and technological sophistication position it as a leader in tissue-based diagnostic innovation.
  • Between 2025 and 2030, the US is expected to maintain its competitive edge through continuous advancement in immunohistochemistry, molecular pathology, and digital pathology solutions..

Key Market Statistics

  • CAGR (2025-2030) 10.0% CAGR
  • Market Size, 2025 ~USD 1454.8 Million
  • Forecast, 2030 ~USD 2339.9 Million
  • Country US

US Tissue Diagnostics Market Overview

Market Valuation :

The US tissue diagnostics market is valued at $1,454.8 million in 2025, demonstrating strong demand for advanced diagnostic solutions across American healthcare institutions.

Robust Growth Trajectory :

With a 10% CAGR through 2030, the US market is projected to reach $2,339.9 million, reflecting accelerating adoption of tissue-based diagnostic technologies in clinical practice.

Advanced Healthcare Infrastructure :

The US benefits from sophisticated laboratory networks, high healthcare spending, and early adoption of cutting-edge diagnostic technologies, driving market expansion.

Clinical Application Expansion :

Increasing utilization in cancer detection, pathology analysis, and personalized medicine initiatives across US hospitals and diagnostic centers fuels sustained market growth.

US Tissue Diagnostics Market Dynamics

  • Major US medical centers and diagnostic laboratories are investing heavily in advanced tissue analysis technologies, including digital pathology and immunohistochemistry platforms.
  • Regulatory support from the FDA and reimbursement improvements further accelerate market penetration across both urban and regional healthcare facilities. Key growth drivers include the aging US population, heightened awareness of early disease detection, and integration of AI-powered diagnostic tools in pathology workflows.
  • Strategic partnerships between diagnostic companies and US healthcare systems, combined with technological innovations in tissue preservation and analysis, will continue to propel market growth.
  • The shift toward value-based care models incentivizes adoption of accurate tissue diagnostics for improved patient outcomes..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • The US tissue diagnostics market will grow from $1,454.8M (2025) to $2,339.9M (2030) at a 10.0% CAGR.
      • The US market is driven by rising cancer prevalence and increased adoption of precision medicine approaches.
      • The US healthcare infrastructure and regulatory environment support rapid innovation in tissue diagnostic technologies.
      • The US represents a mature, high-value market with strong demand for advanced pathology and molecular diagnostic solutions.

      Tissue Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment ANTIBODIES (Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10% from 2025 to 2030
      Largest Segment CONSUMABLES (Product & Service)
      Market Size Base Year (Billions) ~USD 6.74 (2025)
      Revenue Forecast (Billions) ~USD 10.86 (2030)
      Segments Covered Product & Service, Type, Technology, Disease, Sample Type, End User

      US Tissue Diagnostics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product & Service

      • Consumables
      • Instruments
      • Services
      • Software

      By Type

      • Animal Immunohistochemistry Kits
      • Antibodies
      • Blocking Sera And Reagents
      • Chromogenic Substrates
      • Digital Pathology Scanners
      • Diluents
      • Fixation Reagent
      • H&E Stainers
      • Human Immunohistochemistry Kits
      • Ihc Stainers
      • Kits
      • Microtomes
      • Organic Solvents
      • Other Instruments
      • Other Reagents
      • Primary Antibodies
      • Probes
      • Proteolytic Enzymes
      • Reagents
      • Secondary Antibodies
      • Slide-Staining Systems
      • Special Stainers
      • Tissue-Processing Systems

      By Technology

      • Digital Pathology
      • Immunohistochemistry (Ihc)
      • In Situ Hybridization (Ish)
      • Special Staining

      By Disease

      • Breast Cancer
      • Gastric Cancer
      • Lymphoma
      • Non-Small Cell Lung Cancer
      • Other Diseases
      • Prostate Cancer

      By Sample Type

      • Breast Samples
      • Dermatology Samples
      • Gi Samples
      • Gynecological Samples
      • Lung Samples
      • Other Samples
      • Urological Samples

      By End User

      • Contract Research Organizations
      • Hospitals
      • Other End Users
      • Pharmaceutical Companies
      • Research Laboratories

      Target Audience

      • Diagnostic Equipment Manufacturers : Manufacturers need US market data to benchmark product positioning, identify growth segments, and develop go-to-market strategies for tissue diagnostic platforms.
      • Healthcare System Administrators : Hospital and laboratory leaders require market insights to justify capital investments in tissue diagnostics infrastructure and optimize pathology department operations.
      • Investment & Private Equity Firms : Investors evaluating acquisitions or funding opportunities in the US diagnostics sector need comprehensive market sizing and growth projections for due diligence.
      • Pathology & Laboratory Professionals : Pathologists and lab directors use market intelligence to stay informed on emerging technologies, best practices, and industry trends shaping US diagnostic services.
      • Healthcare Consultants & Advisors : Consulting firms advising healthcare clients require detailed US market data to develop strategic recommendations and competitive positioning strategies.

      Key Companies in the US Tissue Diagnostics Market

      CompanyHQOwnershipStrongest segments
      MEDIMMUNEUnited StatesPrivate CompanySynagis (palivizumab) and RSV franchise including MEDI8897,IMFINZI (durvalumab) oncology,Influenza vaccines (FluMist Quadrivalent and Trivalent T/LAIV),
      PHILIPSNetherlandsPublic CompanyDiagnosis & Treatment (Imaging and Image-Guided Therapy),Connected Care (Monitoring, Enterprise Informatics, Sleep and Respiratory Care),Personal Health,
      CERNOSTICSUnited StatesPrivate CompanyTissueCypher Barrett’s clinical testing,Research-use and exploratory tissue analytics,Other potential or legacy pathology services,
      SIENNA CANCER DIAGNOSTICSAustraliaPrivate CompanyhTERT bladder cancer diagnostic test,Other assays, services, and R&D-related income,
      GENOMIC HEALTH INCUnited StatesPrivate CompanyOncotype DX Breast,Oncotype DX Colon,Prostate and other oncology assays,
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction solutions),Life Sciences (genomics, analytical instruments, and research tools),Diagnostics (clinical instruments, consumables, and software),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      MERCK KGAAGermanyPublic CompanyLife Science (tools, reagents, bioprocessing, CDMO),Healthcare (specialty pharma and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases),
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (syringes, needles, catheters, sharps, enteral),Connected Care (infusion, medication management, automation, informatics),BioPharma Systems (prefillable drug delivery systems),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,

      MEDIMMUNE

      Medimmune is a private company founded in 1987 in the United States with 2,359 employees.

      PHILIPS

      Philips is a public company founded in 1891 in the Netherlands with 64,317 employees.

      CERNOSTICS

      Cernostics is a private company founded in 2008 in the United States.

      SIENNA CANCER DIAGNOSTICS

      Sienna Cancer Diagnostics is a private company founded in 2002 in Australia.

      GENOMIC HEALTH INC

      Genomic Health Inc is a private company founded in 2000 in the United States with 829 employees.

      DANAHER CORPORATION

      Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public company founded in 1999 in the United States with 18,000 employees.

      MERCK KGAA

      Merck KGaA is a public company founded in 1668 in Germany with 59,077 employees.

      ABBOTT

      Abbott is a public company founded in 1888 in the United States with 115,000 employees.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company is a public company founded in 1897 in the United States with 72,000 employees.

      SYSMEX CORPORATION

      Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees.

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise valuation metrics for the US tissue diagnostics market with verified 2025-2030 forecasts, enabling accurate financial planning and investment decisions.
      • Competitive Landscape Intelligence : Understand market dynamics specific to the US healthcare system, including key players, market consolidation trends, and competitive positioning strategies.
      • Regulatory & Reimbursement Insights : Gain detailed analysis of FDA approvals, Medicare/insurance reimbursement policies, and compliance requirements affecting tissue diagnostics adoption in the US.
      • Clinical Application Trends : Identify emerging use cases in cancer detection, personalized medicine, and pathology automation driving demand across US hospitals and diagnostic centers.
      • Strategic Market Opportunities : Discover high-growth segments, underserved regions, and partnership opportunities within the US tissue diagnostics ecosystem for market expansion.

      Frequently asked questions

      What is the current size of the US tissue diagnostics market?

      The US tissue diagnostics market is valued at $1,454.8 million in 2025 and is expected to reach $2,339.9 million by 2030.

      What is the projected growth rate for the US tissue diagnostics market?

      The US tissue diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2030.

      What factors are driving growth in the US tissue diagnostics market?

      Key drivers include rising cancer incidence, increasing demand for precision medicine, advanced healthcare infrastructure, and regulatory support for innovative diagnostic platforms in the US.

      Which diagnostic technologies are most prevalent in the US market?

      The US market is dominated by immunohistochemistry, molecular pathology, digital pathology, and advanced tissue-based diagnostic solutions.

      How does the US tissue diagnostics market compare to global trends?

      The US market represents a mature, high-value segment with faster adoption of advanced technologies compared to global averages, driven by strong healthcare spending and innovation.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the global tissue diagnostics market.

      Exhaustive secondary research was done to collect information on the global tissue diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the global tissue diagnostics market.

      Four steps involved in estimating the market size are as follows:/p>

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry's value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      Tissue Diagnostics Market Size, and Share

      Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.

      Note 2: Companies are classified into tiers based on their total revenue. Here's the breakdown of tiers:

      Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both the top-down and bottom-up approaches were used to estimate and validate the global tissue diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

      • The key players in the industry have been identified through extensive secondary research.
      • The revenues generated by leading players operating in the tissue diagnostics market have been determined through primary and secondary research.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

      The research methodology used to estimate the market size included the following:

      Tissue Diagnostics Market : Top-Down and Bottom-Up Approach

      Tissue Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Tissue-based diagnostic tests are performed for screening, diagnosing, and monitoring the response of cancer patients to therapy. Tissue diagnosis refers to the examination of intact tissues obtained during a medical procedure, such as biopsies and surgeries. Tissue-based diagnostic tests are used in the treatment of breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other diseases (bone cancer, cervical cancer, colon cancer, cervix cancer, gallbladder carcinoma, skin cancer, HBV, Epstein-Barr virus, hepatitis, and muscular dystrophies). These diagnostic tests are carried out to identify a medical condition in its early stage so as to establish the correct course of treatment. Tissue diagnostic tests are also carried out to determine the course of recovery and response to the treatment.

      Key Stakeholders

      • Senior Management
      • End Users
      • Finance/Procurement Department
      • R&D Department

      Report Objectives

      • To define, describe, segment, and forecast the global tissue diagnostics market by product & service, technology, disease type, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the global tissue diagnostics market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
      • To benchmark players within the global tissue diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Customization Options:

      MarketsandMarkets offers the following customizations for this market report.

      Country Information

      • Additional country-level analysis of the global tissue diagnostics market Company profiles

      Company profiles

      • Additional five company profiles of players operating in the global tissue diagnostics market
      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the global tissue diagnostics market

       

      Get the Full Tissue Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Tissue Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status